Pharmaceuticals
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology
SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory mul...
2025-10-08 08:15
1958
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized...
2025-10-07 20:30
2530
FDA Lifts Clinical Hold on NUZ-001
Highlights: * U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS * Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 * IND supported by robust preclinical safety data and comprehensive manufacturing and ...
2025-10-06 14:06
3008
MedHub-AI Announces National Reimbursement Approval in Japan for AutocathFFR™
TEL AVIV, Israel, Oct. 3, 2025 /PRNewswire/ -- MedHub-AI
2025-10-03 07:00
1966
Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
* The AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same conditions as the reference product ACTEMRA® (tocilizumab) * AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the FDA * This launch stre...
2025-10-02 20:30
2354
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
* Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 2025 1-3 * MSA is a rare, rapidly progressing, neurodegenerative disease...
2025-10-02 16:41
1854
MD Logistics Makes Largest Indiana Business Location Fully cGMP-compliant
- Total Area of 37,000m2, Enhanced Pharmaceutical Logistics Capacity - TOKYO, Oct. 1, 2025 /PRNewswire/ -- MD Logistics LLC (hereinafter "MD Logistics"), a group company of NIPPON EXPRESS HOLDINGS, INC., completed renovation of the South Area of its largest logistics base inPlainfield, in the U....
2025-10-01 15:00
1824
Major Health Management Wins the 2025 Health Brand Awards - Excellence Award in Health Technology (Health Examination Platform): 38 Years of Quality Commitment, Transforming into a Leading Health Technology Pioneer
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- Taiwan's leading health management brand, Major Health Management, has been honored with the Excellence Award in Health Technology – Health Examination Platform at the 2025 Health Brand Awards. This award is a highly regarded annual recognition in the health i...
2025-10-01 14:51
2255
TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world's first Apixaban Oral Dissolving Film (ODF). This submission marks a significant re...
2025-10-01 14:16
1799
Telix Announces Record-Breaking Presence at EANM 2025
MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (E...
2025-10-01 13:57
2485
Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol
* Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living inSingapore. * Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management. [1] * Beat the Blo...
2025-09-30 10:00
1457
Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams
New IBD research shows that, even during clinical remission, people living with Crohn's diseasecontinue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endo...
2025-09-30 10:00
2655
Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities
* Series C led by Junson Capital along with new investor syndicate and existing shareholders * Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities inBelgium * Additional debt financing provides an alternative financing solution for Ful...
2025-09-30 08:00
2104
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...
2025-09-29 20:48
1716
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gile...
2025-09-29 17:45
2031
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Viva Biotech announced today that it has been honored...
2025-09-29 17:00
2018
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition...
2025-09-29 12:58
2346
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
4421
Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence
SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...
2025-09-26 09:45
3684
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
2350
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
7682
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
7533
IBM and U.S. Department of Commerce Announce America's First Purpose-Built Quantum Foundry, Supported by Proposed $1 Billion CHIPS Award
2026-05-21 20:11
6681
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6640
